Tsubota Laboratory Incorporated
4890・Growth Market・Pharmaceuticals
Governance
The company is a company with a board of corporate auditors, comprising four directors (including one outside director). It has established a voluntary compensation committee (chaired by an independent outside director, and comprising one outside director and three outside corporate auditors), and the board of corporate auditors consists entirely of three outside corporate auditors.
Risk Management
The Risk and Compliance Committee meets semi-annually to identify, evaluate, and manage risks. The company recognizes uncertainties in research and development, intellectual property protection, regulatory compliance, human resource acquisition, information management, and changes in the fund-raising environment as key risks, and has established a system whereby the findings and assessments identified by each department are reported to the Management Committee and the Board of Directors.
Shareholder Returns
Both FY2026 (ending March 2026) and FY2027 (ending March 2027) forecasts call for no dividend (annual dividend of ¥0). The company continues its policy of prioritizing R&D investment and securing internal reserves. No share buybacks have been implemented to date.
Dividend Policy
For the time being, the company does not intend to pay dividends, prioritizing the securing of funds through internal reserves for clinical trial research expenses, basic research expenses, and other costs. In the future, if stable earnings become achievable and sufficient profit is secured to cover R&D funding needs, the company will consider dividend payments after comprehensively weighing factors such as the need to build up internal reserves. When dividends are paid, the company envisions two payments per year: a year-end dividend (resolved at the shareholders' meeting) and an interim dividend (resolved by the Board of Directors). Actual results for FY2025 (ended March 2025) and FY2026 (ending March 2026), as well as the forecast for FY2027 (ending March 2027), all indicate an annual dividend of ¥0.
ESG
With the purpose of "making the future 'gokigen' (delightful) through VISIONary INNOVATION," the company contributes to the SDGs (Goals 3, 4, and 9) by addressing medical challenges such as myopia, dry eye, presbyopia, and brain disorders. In talent acquisition, the company keeps its doors open regardless of nationality, gender, or age, and is working on internal environment improvements such as work-from-home and flextime systems as well as promoting diversity, although specific numerical indicators and targets have not yet been set.
Last updated: June 19, 2026